Integra LifeSciences Holdings (IART) Peer Comparison
$11.99
$-0.11
(-0.91%)
As on 27-Oct-2026 16:27EDT
Market cap
$926 Mln
Revenue (TTM)
$1,657 Mln
P/E Ratio
70.1
P/B Ratio
1.2
Div. Yield
0 %
Edit
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
926 | 236 | 250,149 | 179,441 | 161,511 |
Revenue ($ Mln) |
1,657 | 35 | 47,351 | 48,229 | 25,608 |
Net Profit ($ Mln) |
13.01 | 10.64 | 7,083.00 | 4,701.00 | 4,331.00 |
Net Margin (%) |
0.79 | 30.48 | 14.96 | 9.75 | 16.91 |
RoE (%) |
1.23 | 17.68 | 13.25 | 18.06 | 8.13 |
Price to Earnings |
70.06 | 22.22 | 36.61 | 38.55 | 38.04 |
Price-To-Book |
1.19 | 2.00 | 4.67 | 3.58 | 2.96 |
Income Statement ($ Mln)
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,656.79 | 34.92 | 47,351.00 | 48,229.00 | 25,608.00 |
|
Cost of Revenue
|
787.58 | 14.77 | 27,729.00 | 20,681.00 | 10,603.00 |
|
Gross Profit
|
845.23 | 22.00 | 18,239.00 | 24,607.00 | 14,970.00 |
|
Operating Expenses
|
234.74 | 9.69 | 11,106.00 | 20,197.00 | 9,787.00 |
|
Operating Profit (EBIT)
|
634.47 | 10.45 | 8,515.00 | 7,351.00 | 5,218.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
22.31 | 12.98 | 7,869.00 | 6,562.00 | 4,818.00 |
|
Provision for Tax
|
9.30 | 2.33 | 742.00 | 1,861.00 | 487.00 |
|
Profit after Tax (Net Income)
|
13.01 | 10.64 | 7,083.00 | 4,701.00 | 4,331.00 |
|
Minority Interest
|
0.00 | 0.00 | -16.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 1,964.00 | 1,776.00 | 1,197.00 |
Liabilities ($ Mln)
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,066.62 | 0.00 | 54,767.00 | 0.00 | 53,621.00 |
|
Minority Interest
|
0.00 | 0.00 | -16.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
2,112.18 | 0.00 | 45,296.00 | 0.00 | 30,610.00 |
|
Current Liabilities
|
329.00 | 0.00 | 14,170.00 | 0.00 | 9,050.00 |
|
Total Liabilities
|
3,602.00 | 122.54 | 110,343.00 | 86,713.00 | 83,464.00 |
Assets ($ Mln)
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,317.86 | 0.00 | 88,618.00 | 0.00 | 78,494.00 |
|
Current Assets
|
1,189.94 | 0.00 | 25,615.00 | 0.00 | 14,787.00 |
|
Total Assets
|
3,602.00 | 122.54 | 110,343.00 | 86,713.00 | 83,464.00 |
|
Total Debt*
|
2,002.27 | 0.00 | 41,370.00 | 0.00 | 26,482.00 |
|
Net Current Assets
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
50.38 | 14.69 | 7,818.00 | 9,566.00 | 6,416.00 |
|
Cash Flow from Investing Activities
|
-108.06 | -0.37 | -4,047.00 | -2,422.00 | -1,196.00 |
|
Cash from Financing Activities
|
28.34 | -12.34 | 1,801.00 | -6,309.00 | -2,961.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-15.64 | 9.51 | 7.69 | 10.03 | 5.25 |
|
ROE (%)
|
1.23 | 17.68 | 13.25 | 18.06 | 8.13 |
|
ROA (%)
|
0.30 | 17.03 | 5.50 | 9.52 | 4.46 |
|
EBIT Margin (%)
|
4.84 | 37.16 | 13.63 | 11.82 | 15.27 |
|
Net Margin (%)
|
0.79 | 30.48 | 14.96 | 9.75 | 16.91 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.84 | -9.62 | 8.27 | 10.00 | 5.52 |
|
EBIT Growth (%)
|
117.29 | -6.51 | -24.37 | -34.24 | -12.03 |
|
Net Profit Growth (%)
|
102.63 | -8.42 | 7.81 | -66.37 | 23.64 |
|
EPS Growth (%)
|
102.53 | -5.51 | 9.68 | -66.31 | 26.16 |
|
Book Value Growth (%)
|
0.41 | -- | 9.37 | -- | 6.02 |
Valuation Ratios
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.85 | 15.86 | 32.43 | 33.55 | 45.04 |
|
Price / Book Value
|
0.91 | 1.50 | 4.09 | 4.20 | 3.10 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-8.37 | 5.48 | 21.61 | 18.87 | 25.42 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.29 | 0.00 |
|
Short term debt to equity ratio
|
0.06 | -- | 0.04 | 0.06 | 0.04 |
|
Current Ratio
|
3.62 | 37.62 | 1.81 | 1.58 | 1.63 |
|
Quick Ratio
|
2.21 | 34.57 | 1.41 | 1.18 | 1.29 |
|
Interest Coverage
|
1.23 | -- | 6.12 | 8.37 | 14.38 |
Operating Efficiency Ratios
| Integra LifeSciences Holdings (IART) | Utah Medical Products (UTMD) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.03 | 0.00 | 20.33 | 0.00 | 20.02 |
|
Asset Turnover
|
0.38 | 0.56 | 0.37 | 0.98 | 0.26 |
|
Receivable days
|
61.56 | 36.11 | 82.76 | 61.20 | 61.72 |
|
Inventory Days
|
213.10 | 185.15 | 72.19 | 117.44 | 91.69 |
|
Payable days
|
41.20 | 16.07 | 46.50 | 78.11 | 68.44 |
|
Cash Conversion Cycle
|
233.46 | 205.18 | 108.45 | 100.53 | 84.97 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
